Clinico-biological Collection of Bone, Calcium and Growth Plate Pathologies (OSCAR)

Creation of a Biological Collection to Study the Pathophysiology and Identify Predictive Factors for the Evolution of Bone, Calcium and Growth Plate Pathologies

The aim of this project is to set up a biological and clinical collection of patients with progressive bone, calcium and growth plate pathologies.

This collection will provide a better understanding of the mechanisms involved in growth plate and bone damage in these diseases and identify factors predictive of progression and new therapeutic targets.

Study Overview

• Status: Recruiting
• Conditions: Bone Disorder
• Intervention / Treatment: Other: Biological; Other: Biological samples

• Study Type: Observational
• Enrollment (Estimated): 350

Contacts and Locations

• Study Contact: Name: Thomas EDOUARD, MD; Phone Number: +33 0534558555; Email: edouard.t@chu-toulouse.fr
• Study Contact Backup: Name: Sanaa EDDIRY; Phone Number: +33 0561776110; Email: eddiry.s@chu-toulouse.fr

Study Locations

• France
  • Toulouse, France, 31000
    • Recruiting
    • University Toulouse Hospital
    • Contact: Thomas EDOUARD, MD
    • Contact: Thomas EDOUARD, MD; Phone Number: +33 0534558555; Email: edouard.t@chu-toulouse.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with with growth plate or bone pathology.

Description

Inclusion Criteria:

• Children (from birth) with growth plate or bone pathology
• Patients affiliated to or benefiting from a social security scheme
• Patients able to receive information about the study and to understand the information form in order to participate in the study. This implies :
• mastery of the French language
• Not being subject to a restriction of rights by the judicial authorities
• Patients or legal representatives having given their consent to participate in the study (expression of non-opposition).

Exclusion Criteria:

• Patients under legal protection (guardianship, curatorship or safeguard of justice)
• Pregnant or breast-feeding women

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients suffering from growth plate or bone pathology; As part of their pathology, patients benefit from clinical monitoring and regular blood and urine tests.	Other: Biological; Surgical residues may be preserved in the event of surgery carried out as part of the treatment.; Other: Biological samples; Blood and urine will be taken in larger quantity

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Building a collection of biological samples and clinical-biological data from patients presenting bone, calcium and growth plate pathologies	Blood and urine sampling	Day 0 and through study completion, an average of 5 years

Secondary Outcome Measures

Outcome Measure	Time Frame
Identification of potential markers of disease progression based on new knowledge.	Day 0 and through study completion, an average of 5 years

Collaborators and Investigators

• Sponsor: University Hospital, Toulouse
• Investigators: Principal Investigator: Thomas EDOUARD, MD, CHU Toulouse

Study record dates

Study Major Dates

• Study Start (Actual): September 16, 2024
• Primary Completion (Estimated): September 16, 2034
• Study Completion (Estimated): September 16, 2034

Study Registration Dates

• First Submitted: May 30, 2024
• First Submitted That Met QC Criteria: May 30, 2024
• First Posted (Actual): June 5, 2024

Study Record Updates

• Last Update Posted (Actual): September 25, 2024
• Last Update Submitted That Met QC Criteria: September 23, 2024
• Last Verified: September 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Bone Diseases
• Other Study ID Numbers: RC31/24/0214

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No